AU2020407070A1 - Combinations - Google Patents

Combinations Download PDF

Info

Publication number
AU2020407070A1
AU2020407070A1 AU2020407070A AU2020407070A AU2020407070A1 AU 2020407070 A1 AU2020407070 A1 AU 2020407070A1 AU 2020407070 A AU2020407070 A AU 2020407070A AU 2020407070 A AU2020407070 A AU 2020407070A AU 2020407070 A1 AU2020407070 A1 AU 2020407070A1
Authority
AU
Australia
Prior art keywords
unsubstituted
substituted
alkyl
group
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020407070A
Other languages
English (en)
Inventor
Brant Clayton BOREN
Kevin Duane Bunker
Fernando Donate
Peter Qinhua HUANG
Hooman IZADI
Jiali Li
Joseph Robert Pinchman
Ahmed Abdi Samatar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recurium IP Holdings LLC
Original Assignee
Recurium IP Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium IP Holdings LLC filed Critical Recurium IP Holdings LLC
Publication of AU2020407070A1 publication Critical patent/AU2020407070A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
AU2020407070A 2019-12-20 2020-12-16 Combinations Abandoned AU2020407070A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962952039P 2019-12-20 2019-12-20
US62/952,039 2019-12-20
PCT/US2020/065409 WO2021127044A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (1)

Publication Number Publication Date
AU2020407070A1 true AU2020407070A1 (en) 2022-07-14

Family

ID=76478095

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020407070A Abandoned AU2020407070A1 (en) 2019-12-20 2020-12-16 Combinations

Country Status (12)

Country Link
US (1) US20230008362A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069235A4 (cg-RX-API-DMAC7.html)
JP (1) JP7631348B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220119442A (cg-RX-API-DMAC7.html)
CN (1) CN115427042A (cg-RX-API-DMAC7.html)
AU (1) AU2020407070A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012281A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165472A1 (cg-RX-API-DMAC7.html)
IL (1) IL294080A (cg-RX-API-DMAC7.html)
MX (1) MX2022007626A (cg-RX-API-DMAC7.html)
TW (1) TW202132299A (cg-RX-API-DMAC7.html)
WO (1) WO2021127044A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020018286A2 (pt) 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
WO2021097139A1 (en) 2019-11-15 2021-05-20 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
KR20230038523A (ko) 2020-07-09 2023-03-20 리커리엄 아이피 홀딩스, 엘엘씨 Wee1 억제제의 염 및 형태
WO2023083194A1 (zh) * 2021-11-09 2023-05-19 杭州格博生物医药有限公司 Wee1蛋白激酶降解剂及其用途
JP2024546584A (ja) * 2021-12-15 2024-12-26 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Bcl-2阻害剤、wee-1阻害剤及び他の化学療法剤の三剤療法の組み合わせ
WO2025193930A1 (en) * 2024-03-14 2025-09-18 Zeno Management, Inc. Wee1 inhibitor combination therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015183776A1 (en) 2014-05-29 2015-12-03 Merck Sharp & Dohme Corp. Methods for treating cancer with a wee1 inhibitor
MX2020001235A (es) * 2017-08-01 2020-07-20 Recurium Ip Holdings Llc Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
IL316472A (en) 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
BR112020018286A2 (pt) 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
JP2024546584A (ja) * 2021-12-15 2024-12-26 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Bcl-2阻害剤、wee-1阻害剤及び他の化学療法剤の三剤療法の組み合わせ

Also Published As

Publication number Publication date
IL294080A (en) 2022-08-01
EP4069235A4 (en) 2024-01-10
WO2021127044A1 (en) 2021-06-24
EP4069235A1 (en) 2022-10-12
MX2022007626A (es) 2022-09-23
CN115427042A (zh) 2022-12-02
KR20220119442A (ko) 2022-08-29
JP7631348B2 (ja) 2025-02-18
US20230008362A1 (en) 2023-01-12
CA3165472A1 (en) 2021-06-24
BR112022012281A2 (pt) 2022-08-30
JP2023508328A (ja) 2023-03-02
TW202132299A (zh) 2021-09-01

Similar Documents

Publication Publication Date Title
JP7750526B2 (ja) 組み合わせ
EP4069235A1 (en) Combinations
EP4069225A1 (en) Combinations
WO2021231653A1 (en) Mono- and combination therapies
JP2023508327A (ja) 組み合わせ
CA3165479A1 (en) Combinations
US20230065577A1 (en) Combinations
RU2840819C1 (ru) Комбинации
US20230158048A1 (en) Combinations
US20230381172A1 (en) Combinations of bcl-2 inhibitors with chemotherapeutic agents
US20230054767A1 (en) Combinations

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application